Table 3 Disease characteristics,... | American Society of Hematology

Table 3

Disease characteristics, clinical course, and outcomes in OAML

Reference, year	No. of patients	Stage I, %	CR, %	LR, %	DR, %	TTP, mo	Survival, %	LRM, %
White et al,⁴ 1995	15	87	77	0	13	24	ND	0
Galieni et al,⁷¹ 1997	15	100	93	20	0	66	5-y OS 93, DSS 100	0
Nakata et al,¹² 1999	35	91	ND	ND	ND	ND	5-y DSS 100	3
Jenkins et al,⁹ 2000	82	82	ND	ND	27	63	5-y PFS 53, DSS 87	12
Auw-Haedrich et al,⁴⁵ 2001	38	84	59	6	26	ND	ND	16
McKelvie et al,⁶ 2001	44	91	ND	5	17	52	ND	2
Cho et al,¹¹ 2003	61	83	41	7	5	40	ND	2
Tsang et al,⁶⁸ 2003	30	97	97	17	10	ND	5-y DFS 74, OS 97	ND
Wenzel et al,⁸⁶ 2003	20	85	60	5	30	8	ND	ND
Zucca et al,⁸⁷ 2003	31	87	ND	ND	ND	ND	5-y PFS 100, DSS 100*	0
							5-y PFS 23, DSS 87†	13
Coupland et al,⁷ 2005	136	86	ND	23	32	20	ND	13
Rosado et al,⁴² 2006	55	84	98	7	15	19	5-y PFS 79, OS 96	2
Tanimoto et al,⁵⁴ 2007	114	94	79	22	5	ND	10-y PFS 57, OS 89	3
Yoon et al,¹⁷ 2007	60	90	90	13	2	58	10-y DFS 83, DSS 96	3

Reference, year	No. of patients	Stage I, %	CR, %	LR, %	DR, %	TTP, mo	Survival, %	LRM, %
White et al,⁴ 1995	15	87	77	0	13	24	ND	0
Galieni et al,⁷¹ 1997	15	100	93	20	0	66	5-y OS 93, DSS 100	0
Nakata et al,¹² 1999	35	91	ND	ND	ND	ND	5-y DSS 100	3
Jenkins et al,⁹ 2000	82	82	ND	ND	27	63	5-y PFS 53, DSS 87	12
Auw-Haedrich et al,⁴⁵ 2001	38	84	59	6	26	ND	ND	16
McKelvie et al,⁶ 2001	44	91	ND	5	17	52	ND	2
Cho et al,¹¹ 2003	61	83	41	7	5	40	ND	2
Tsang et al,⁶⁸ 2003	30	97	97	17	10	ND	5-y DFS 74, OS 97	ND
Wenzel et al,⁸⁶ 2003	20	85	60	5	30	8	ND	ND
Zucca et al,⁸⁷ 2003	31	87	ND	ND	ND	ND	5-y PFS 100, DSS 100*	0
							5-y PFS 23, DSS 87†	13
Coupland et al,⁷ 2005	136	86	ND	23	32	20	ND	13
Rosado et al,⁴² 2006	55	84	98	7	15	19	5-y PFS 79, OS 96	2
Tanimoto et al,⁵⁴ 2007	114	94	79	22	5	ND	10-y PFS 57, OS 89	3
Yoon et al,¹⁷ 2007	60	90	90	13	2	58	10-y DFS 83, DSS 96	3

CR indicates complete remission rate; LR, local recurrence rate; DR, distal recurrence rate; TTP, time to progression; LRM, lymphoma-related mortality; ND, not determined; OS, overall survival rate; DSS, disease-specific survival rate; PFS, progression-free survival rate; and DFS, disease-free survival rate.

Conjunctival.

†

Orbital.

View Large

This Feature Is Available To Subscribers Only